{"nctId":"NCT00224107","briefTitle":"A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo","startDateStruct":{"date":"2005-05"},"conditions":["Benign Prostatic Hyperplasia (BPH)"],"count":461,"armGroups":[{"label":"Silodosin","type":"EXPERIMENTAL","interventionNames":["Drug: Silodosin"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Silodosin","otherNames":["Rapaflo"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males in good general health and at least 50 years of age, with symptoms of moderate to severe benign prostatic hyperplasia.\n\nExclusion Criteria:\n\n* Medical conditions that would confound the efficacy evaluation.\n* Medical conditions in which it would be unsafe to use an alpha-blocker.\n* The use of concomitant drugs that would confound the efficacy evaluation.\n* The use of concomitant drugs that would be unsafe with this alpha-blocker.","healthyVolunteers":false,"sex":"MALE","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"International Prostate Symptom Score (IPSS)","description":"Change from baseline In IPSS at Week 12. IPSS uses a 0 to 35 scale; 0 best, 35 worse symptoms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":"5.38"},{"groupId":"OG001","value":"21.4","spread":"4.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"6.73"},{"groupId":"OG001","value":"-3.6","spread":"5.85"}]}]}]},{"type":"SECONDARY","title":"Maximum Urine Flow Rate (Qmax)","description":"Change from baseline in maximum urine flow rate (Qmax)at Week 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"2.60"},{"groupId":"OG001","value":"9.0","spread":"2.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"4.31"},{"groupId":"OG001","value":"1.2","spread":"3.81"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":233},"commonTop":["Retrograde ejaculation","Nasopharyngitis","Headache","Orthostatic hypotension","Dizziness"]}}}